FarmaKology-Amgen to acquire ChemoCentryx for $4 billion

FarmaKology-Amgen to acquire ChemoCentryx for $4 billion

Novo Banking

Today's Company

ِِِAbCellera

AbCellera

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. Its full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. We partner with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.

News

Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

CHOP Helps Develop Platform to Speed Up Drug Development for Kids with Cancer

Children's Hospital of Philadelphia has helped launch a new computational platform that will harmonize pediatric cancer data, allowing researchers, pharmaceutical companies, and advocacy groups to accelerate the pace of drug development for pediatric cancer. With funding from the National Cancer Institute (NCI) via a subcontract with Leidos Biomedical Research, current operator of the NCI's Frederick National Laboratory for Cancer Research, CHOP researchers have created the Molecular Targets Platform to facilitate pediatric research in response to the Research to Accelerate Cures and Equity (RACE) for Children Act, which requires companies to test cancer drugs in children that are used in adults when there is a shared molecular target.

Amgen to acquire ChemoCentryx for $4 billion

Amgen  and ChemoCentryx, Inc., a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.

Looking east, Sanofi pens 'pioneering' cancer drug partnership with China's Innovent

Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. Innovent is a leading biopharmaceutical company with strong clinical development capabilities and a broad commercial footprint in China. Both companies are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III SAR408701 (tusamitamab ravtansine; anti-CEACAM5 antibody-drug conjugate) and Phase II SAR444245 (non-alpha IL-2), combining with sintilimab, the leading checkpoint inhibitor in China.

Research & Study

New Computer Modeling Could Boost Drug Discovery

Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer

Polymer-embedded copper-based nanoparticles prevent surface contamination by viruses

Podcast

Last month, Fierce hosted an event to talk with experts across the industry about what's beyond the leading edge of biotech and pharma. This week's episode brings you discussion from four of the panel discussions. Our first panel focused on Alzheimer’s disease, where success is hard to come by. The panelists discussed the learnings that can come from past failures. We also had a panel about the industry’s environmental impact. As more companies are rolling out programs to cut carbon emissions, reduce waste and plug into alternative energy sources, we asked sustainability experts if pharma is doing enough and what more needs to be done. You'll also hear from our panelists on cell and gene therapies and why pricing concerns still loom. Only a few such therapies have made it to market so far. But as more hit the scene, insurers and pharmaceutical companies need to think about how to pay for them to avoid sticker shock. Finally, the use of artificial intelligence (AI) methods in drug research and development is really starting to take off. Businesses are increasingly using AI tools to find drugs—and it is working faster and more efficiently. We'll explore AI's evolution in drug discovery.

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

Automated High-Throughput Protein and Antibody Purification ­­— A Scalable and Cost-Effective Solution

GMP Analytical Testing in Gene Therapy Products

Video

FarmaKology